Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board
FAST welcomes Dr. Nick France, a rare disease drug development leader from Alexion, AstraZeneca Rare Disease, to its Board of Directors, bringing two decades of biopharmaceutical and gene therapy expertise.
FAST Announces Funding For First Innovative Seed Grant
FAST has awarded its first Innovative Seed Grant to Drs. Rachel Cunningham and Jennifer Adair to develop a safer, more accessible hematopoietic stem cell therapy approach for Angelman syndrome that avoids risky chemotherapy-based conditioning.